ALXO - CIK 0001810182
The table below shows ALX ONCOLOGY HOLDINGS INC's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$84.14M | -$121.91M | -$130.36M | -$89.22M | -$68.10M | -$38.29M |
| Capital expenditure | $212.00K | $447.00K | $1.27M | $1.43M | $666.00K | $31.00K |
| Investing cash flow | $82.59M | $86.26M | $44.66M | -$235.42M | -$4.92M | $610.00K |
| Dividends paid | - | - | - | - | - |
ALX ONCOLOGY HOLDINGS INC reported operating cash flow of -$84.14M for fiscal year 2025. That is up 31.0% from -$121.91M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$13.19M (FY 2018) to -$84.14M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $362.00K | $30.82M | $59.29M | $9.86M | $2.47M | $462.88M |